Modality
mRNA
MOA
PLK4i
Target
GLP-1R
Pathway
DDR
Cholangiocarcinoma
Development Pipeline
Preclinical
~Feb 2017
→ ~May 2018
Phase 1
Aug 2018
→ Aug 2030
Phase 1Current
NCT03003235
606 pts·Cholangiocarcinoma
2018-08→2030-08·Terminated
606 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-08-184.4y awayInterim· Cholangiocarcinoma
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1
Termina…
Catalysts
Interim
2030-08-18 · 4.4y away
Cholangiocarcinoma
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03003235 | Phase 1 | Cholangiocarcinoma | Terminated | 606 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| VRT-5441 | Vertex Pharma | Phase 3 | GLP-1R |